NEW YORK (GenomeWeb) – San Francisco-based genetic testing company Invitae has filed a prospectus for an initial public offering of its stock for up to $86 million.

Invitae has not priced its shares nor said how many it plans to offer, but said in its Form S-1 filed with the US Securities and Exchange Commission that it plans to trade on the New York Stock Exchange under the symbol "NVTA."

JP Morgan Securities, Cowen and Company, and Leerink Partners are listed as underwriters.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.